BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santos García D, Fernández Pajarín G, Oropesa-ruiz JM, Escamilla Sevilla F, Rahim López RRA, Muñoz Enríquez JG. Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study. Brain Sciences 2022;12:383. [DOI: 10.3390/brainsci12030383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie L, Qi X, Wang X, He B, Wang Y, Zhang W, Yu Z, Deng M, Liang S, Lü M. Adverse event profiles of adjuvant treatment with opicapone in Parkinson's disease: A systematic review and meta-analysis. Front Pharmacol 2022;13:1042992. [PMID: 36506576 DOI: 10.3389/fphar.2022.1042992] [Reference Citation Analysis]
2 Szász JA, Constantin VA, Orbán-kis K, Bancu LA, Bataga SM, Ciorba M, Nagy E, Neagoe MR, Mihály I, Szász RM, Kelemen K, Simu M, Szatmári S. Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: Observations and Dilemmas after 10 Years of Real-Life Experience. Pharmaceutics 2022;14:1115. [DOI: 10.3390/pharmaceutics14061115] [Reference Citation Analysis]